Craig Rogers
Overview
Explore the profile of Craig Rogers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
831
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vigano S, Finati M, Stephens A, Bertini A, Finocchiaro A, Lughezzani G, et al.
Prostate
. 2025 Mar;
:e24882.
PMID: 40066656
Background: Socioeconomic status and geographical location contribute to disparities in localized prostate cancer (PCa) treatment. We examined the impact of area of deprivation index (ADI) on initial treatment type for...
2.
Tinsley S, Stephens A, Morrison C, Richard C, Hares K, Lutchka J, et al.
J Racial Ethn Health Disparities
. 2025 Mar;
PMID: 40048083
Introduction: To assess the utilization and prostate cancer (PCa)-specific mortality (PCSM) between non-Hispanic Black (NHB) and non-Hispanic White (NHW) on active surveillance (AS) with intermediate risk PCa (iPCa). Methods: The...
3.
Soputro N, Okhawere K, Ramos-Carpinteyro R, Calvo R, Wang Y, Manfredi C, et al.
J Endourol
. 2025 Feb;
PMID: 39909476
To develop a patient-specific algorithm to better guide clinical decision-making when considering between single port (SP) and multi-port (MP) robotic partial nephrectomy (RPN). A retrospective review was performed on the...
4.
Cirulli G, Stephens A, Chiarelli G, Finati M, Bertini A, Chase M, et al.
Prostate
. 2025 Jan;
e24856.
PMID: 39869547
Introduction: PSA screening remains a pivotal tool for early prostate cancer (PCa) detection. International guidelines rely on evidence from three major randomized clinical trials: ERSPC, PLCO, and CAP. We aim...
5.
Chiarelli G, Davis M, Stephens A, Finati M, Cirulli G, Morrison C, et al.
Prostate
. 2024 Dec;
85(4):354-363.
PMID: 39651707
Background: Previous studies found that Midlife Baseline PSA (MB PSA) predicts the risk of developing lethal prostate cancer (PCa), although the cohorts were homogenous in terms of racial compositions. We...
6.
Chiarelli G, Stephens A, Finati M, Cirulli G, Tinsley S, Wang Y, et al.
World J Urol
. 2024 Nov;
42(1):646.
PMID: 39589591
Purpose: To assess active surveillance (AS) adherence for prostate cancer (PCa) in a "real-world" clinical practice. Materials And Methods: We utilized our institutional database which was built by interrogating electronic...
7.
Stephens A, Morrison C, Lutchka J, Richard C, Hares K, Tinsley S, et al.
Urology
. 2024 Nov;
197:80-87.
PMID: 39580118
Objective: To examine the frequency and rate at which transfeminine patients receive prostate-specific antigen testing compared to a matched cisgender cohort. Methods: Patients with prostates who had encounters in our...
8.
Finati M, Stephens A, Cirulli G, Chiarelli G, Tinsley S, Morrison C, et al.
JNCI Cancer Spectr
. 2024 Nov;
8(6).
PMID: 39576690
Background: Socioeconomic and demographic factors contribute to disparity in prostate cancer (PCa) outcomes. We examined the impact of Area of Deprivation Index (ADI) and race on PCa incidence and lethality...
9.
Tinsley S, Stephens A, Finati M, Chiarelli G, Cirulli G, Morrison C, et al.
Int Urol Nephrol
. 2024 Nov;
57(3):825-837.
PMID: 39528898
Purpose: This study examined cancer control metrics between surgery and radiation for clinically positive nodal prostate cancer in an other-cause mortality weighted cohort, to circumvent limitations in previous studies. Methods:...
10.
Finati M, Morrison C, Stephens A, Chiarelli G, Cirulli G, Tinsley S, et al.
Prostate
. 2024 Oct;
85(1):82-89.
PMID: 39465565
Background: Non-Hispanic Black (NHB) men are at higher risk both for incidence and mortality from prostate cancer (PCa) compared to Non-Hispanic White (NHW) men, but these findings arise from biopsy-detected...